These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38925918)

  • 21. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
    Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
    J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies.
    Germovsek E; Lutsar I; Kipper K; Karlsson MO; Planche T; Chazallon C; Meyer L; Trafojer UMT; Metsvaht T; Fournier I; Sharland M; Heath P; Standing JF;
    J Antimicrob Chemother; 2018 Jul; 73(7):1908-1916. PubMed ID: 29684147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
    Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
    J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
    Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
    Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A meropenem pharmacokinetics model in patients with haematological malignancies.
    Contejean A; Jaffrelot L; Benaboud S; Tréluyer JM; Grignano E; Willems L; Gauzit R; Bouscary D; Gana I; Boujaafar S; Kernéis S; Hirt D
    J Antimicrob Chemother; 2020 Oct; 75(10):2960-2968. PubMed ID: 32737508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis.
    Ohata Y; Tomita Y; Sunakawa K; Drusano GL; Tanigawara Y
    Int J Antimicrob Agents; 2019 Sep; 54(3):292-300. PubMed ID: 31279154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation.
    Morales Junior R; Mizuno T; Paice KM; Pavia KE; Hambrick HR; Tang P; Jones R; Gibson A; Stoneman E; Curry C; Kaplan J; Tang Girdwood S
    J Antimicrob Chemother; 2024 Oct; 79(10):2668-2677. PubMed ID: 39092928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics.
    Martins FS; Zhu P; Heinrichs MT; Sy SKB
    Br J Clin Pharmacol; 2021 Mar; 87(3):1012-1023. PubMed ID: 32638408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.
    Patel TS; Pogue JM; Mills JP; Kaye KS
    Future Microbiol; 2018 Jul; 13(9):971-983. PubMed ID: 29692218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis.
    Wu G; Cheon E
    Expert Opin Pharmacother; 2018 Sep; 19(13):1495-1502. PubMed ID: 30160990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis.
    An G; Creech CB; Wu N; Nation RL; Gu K; Nalbant D; Jimenez-Truque N; Fissell W; Rolsma S; Patel PC; Watanabe A; Fishbane N; Kirkpatrick CMJ; Landersdorfer CB; Winokur P
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0131222. PubMed ID: 36622154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function.
    Usman M; Frey OR; Hempel G
    Eur J Clin Pharmacol; 2017 Mar; 73(3):333-342. PubMed ID: 27966034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics and probability of target attainment in patients with sepsis under renal replacement therapy receiving continuous infusion of meropenem: Sustained low-efficiency dialysis and continuous veno-venous haemodialysis.
    Westermann I; Gastine S; Müller C; Rudolph W; Peters F; Bloos F; Pletz M; Hagel S
    Br J Clin Pharmacol; 2021 Nov; 87(11):4293-4303. PubMed ID: 33818823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
    Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis.
    Wang ZM; Chen XY; Bi J; Wang MY; Xu BP; Tang BH; Li C; Zhao W; Shen AD
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meropenem population pharmacokinetics in patients with decompensated cirrhosis and severe infections.
    Bastida C; Hernández-Tejero M; Aziz F; Espinosa C; Sanz M; Brunet M; López E; Fernández J; Soy D
    J Antimicrob Chemother; 2020 Dec; 75(12):3619-3624. PubMed ID: 32887993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developmental Population Pharmacokinetics-Pharmacodynamics of Meropenem in Chinese Neonates and Young Infants: Dosing Recommendations for Late-Onset Sepsis.
    Wu YE; Kou C; Li X; Tang BH; Yao BF; Hao GX; Zheng Y; van den Anker J; You DP; Shen AD; Zhao W
    Children (Basel); 2022 Dec; 9(12):. PubMed ID: 36553441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.
    Albin OR; Patel TS; Kaye KS
    Expert Rev Anti Infect Ther; 2018 Dec; 16(12):865-876. PubMed ID: 30372359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
    Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
    Pai MP; Cojutti P; Pea F
    Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.